You are on page 1of 13

Global Anti-Bacterial Drugs Market

Assessment & Forecast:


2015-2019
Segments Assessed:
Orbactiv,

Sivextro,

(Cubicin, Teflaro/Zinforo, Dificid, Dalvance,

Zerbaxa,

Avycaz,

Zyvox,

Avelox,

Augmentin,

Zosyn/Tazocin, Invanz, Tygacil, Surotomycin, Solithromycin, Delafloxacin,


Plazomycin, Taksta, Cadazolid, Carbavance, Eravacycline and Others).

Geographies Assessed: North America, Europe, Asia-Pacific, Latin


America, Middle-East and Africa.

Published: June 2015

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

About Us
Spearhead Acuity Business Research & Consulting (SA-BRC) is a premium Life Science business
intelligence and data analytics firm. The SA-BRC team offers a wide range of business intelligence
services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals,
Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the
entire value chain of healthcare industry. Our research and consulting capabilities extend across
several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical
Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Our skills and capabilities help put forth the most accurate perspective of the market. We track all
major and minor events that create ripples and affect the life-science market in numerous ways. Our
data modeling process includes the evaluation of impacting events and analyzing other invaluable
sources (public & proprietary) of information and finally reporting results that will influence the
decision making of the readers.

SA-BRC has helped start-ups and market leaders across the globe achieve their revenue goals
strategically in multiple stages such as adoption, pre-launch research, regional analysis, social media
analytics, competitive mapping, market entry and post marketing surveillance. We frequently build
panels of experts for gathering data and invite participants of the healthcare industry to share their
opinions and views on our reports. Our current network of industry experts spans across all major
life-science domains and take pride in keeping ourselves abreast with the latest happenings within
the sphere of Life-Science.

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

Table of Content
Chapter 1 Preface
1.1

1.2

Research Scope

10

1.1.2 Postulations

11

Methodology of Research

Chapter 2 Prcis
Market Inferences

Chapter 3 Market Dynamics


3.1

3.2

Market Drivers

12
13

14
14

16
16

3.1.1 Increasing incidence of hospital and community acquired bacterial infections pushing
growth of brands and generics

16

3.1.2 Improving Legal Framework for provision of Incentives expected to drive growth

16

Market Inhibitors
3.2.1 Limited pipeline drugs and absence of new indication targets may lead to significant
erosion against generics

3.3

1.1.1 Market Segmentation

1.2.1 Companies covered in this report

2.1

Opportunities

16
16

17

3.3.1 R&D in treatment of carbapenem-resistant enterobacteria will open new market

17

3.3.2 Existence of Considerable Target Population in Emerging Economies

17

Chapter 4 Global Anti-Bacterial Drugs Market Assessment, by Current


Marketed Brands - Size & Forecast, 2015 2019 (US$
Millions)

18

4.1

Introduction

18

4.2

Cubicin (daptomycin) Market, US$ Mn (2013 - 2019)

18

4.3

Teflaro/Zinforo (ceftaroline) Market, US$ Mn (2013 - 2019)

19

4.4

Dificid (fidaxomicin) Market, US$ Mn (2013 - 2019)

20

4.5

Dalvance (dalbavancin) Market, US$ Mn (2013 - 2019)

21

4.6

Orbactiv (oritavancin) Market, US$ Mn (2013 - 2019)

22

4.7

Sivextro (tedizolid) Market, US$ Mn (2013 - 2019)

23

4.8

Zerbaxa (ceftolozane + tazobactam) Market, US$ Mn (2013 - 2019)

24

4.9

Avycaz (ceftazidime-avibactam) Market, US$ Mn (2013 - 2019)

25

4.10 Zyvox (linezolid) Market, US$ Mn (2013 - 2019)

26

4.11 Avelox (moxifloxacin) Market, US$ Mn (2013 - 2019)

27

4.12 Augmentin (amoxicillin + clavulanic acid) Market, US$ Mn (2013 2019)

28

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

4.13 Zosyn/Tazocin (piperacillin + tazobactam) Market, US$ Mn (2013 2019)

29

4.14 Invanz (ertapenem) Market, US$ Mn (2013 - 2019)

30

4.15 Tygacil (tigecyline) Market, US$ Mn (2013 - 2019)

31

4.16 Other Prominent Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

32

Chapter 5 Global Anti-Bacterial Drugs Market Assessment for Pipeline


Drugs - Size & Forecast, 2015 2019 (US$ Millions)

33

5.1

Introduction

33

5.2

Surotomycin Market, US$ Mn (2013 - 2019)

33

5.3

Solitaire (solithromycin) Market, US$ Mn (2013 - 2019)

34

5.4

Delafloxacin Market, US$ Mn (2013 - 2019)

35

5.5

Plazomycin Market, US$ Mn (2013 - 2019)

35

5.6

Taksta (fusidic acid) Market, US$ Mn (2013 - 2019)

36

5.7

Cadazolid Market, US$ Mn (2013 - 2019)

37

5.8

Carbavance Market, US$ Mn (2013 - 2019)

38

5.9

Eravacycline Market, US$ Mn (2013 - 2019)

39

5.10 Other Early-Stage Anti-Bacterial Candidates

40

5.10.1 Finafloxacin

40

5.10.2 Omadacycline

40

5.10.3 Zabofloxacin

40

5.10.4 Ramoplanin

40

5.10.5 Nemonoxacin

41

5.10.6 Relebactam (MK-7655)

41

Chapter 6 Global Anti-Bacterial Drugs Market Assessment Size &


Forecast, By Geography, 2015 2019 (US$ Millions)

42

6.1

Introduction

42

6.2

North America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

43

6.3

Europe Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

44

6.4

Asia-Pacific Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

45

6.5

Latin America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

46

6.6

Middle-East Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

47

6.7

Africa Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)

48

Chapter 7 Key Players Analysis: Global Anti-Bacterial Drugs Market,


2014 (%)
7.1
7.2

50

Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014


(%)

50

Global Anti-Bacterial Drugs Market: Recent Developments 20132015

51

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

7.3

7.2.1 Mergers and Acquisitions

51

7.2.2 New Product Launches and Approvals

51

Competitive Landscape: Strategies

Chapter 8 Epilogue

53

54

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

List of Figures
FIG. 1

Market Segmentation: Anti-Bacterial Drugs Market Assessment & Forecast (20152019)

10

FIG. 2

Research Methodology: Global Anti-Bacterial Drugs Market Assessment

12

FIG. 3

Global Anti-Bacterial Drugs Market Share, by Geography 2014 & 2019 (% Share - US$
Million)

15

FIG. 4

Global Anti-Bacterial Drugs Market Cubicin (daptomycin) Revenues 2013 2019 (US$
Millions)
19

FIG. 5

Global Anti-Bacterial Drugs Market Teflaro/Zinforo (ceftaroline) Revenues 2013


2019 (US$ Millions)

20

FIG. 6

Global Anti-Bacterial Drugs Market Dificid (fidaxomicin) Revenues 2013 2019 (US$
Millions)

21

FIG. 7

Global Anti-Bacterial Drugs Market Dalvance (dalbavancin) Revenues 2013 2019


(US$ Millions)

22

Global Anti-Bacterial Drugs Market Orbactiv (oritavancin) Revenues 2013 2019


(US$ Millions)

23

FIG. 9

Global Anti-Bacterial Drugs Market Sivextro (tedizolid-phosphate) Revenues 2013


2019 (US$ Millions)

23

FIG. 10

Global Anti-Bacterial Drugs Market Zerbaxa (ceftolozane + tazobactam) Revenues


2013 2019 (US$ Millions)

24

Global Anti-Bacterial Drugs Market Avycaz (ceftazidime-avibactam) Revenues 2013


2019 (US$ Millions)

25

FIG. 12

Global Anti-Bacterial Drugs Market Zyvox (linezolid) Revenues 2013 2019 (US$
Millions)

26

FIG. 13

Global Anti-Bacterial Drugs Market Avelox (moxifloxacin) Revenues 2013 2019 (US$
Millions)
27

FIG. 14

Global Anti-Bacterial Drugs Market Augmentin (amoxicillin + clavulanic acid)


Revenues 2013 2019 (US$ Millions)

28

Global Anti-Bacterial Drugs Market Zosyn/Tazocin (piperacillin + tazobactam)


Revenues 2013 2019 (US$ Millions)

29

FIG. 16

Global Anti-Bacterial Drugs Market Invanz (ertapenem) Revenues 2013 2019 (US$
Millions)

30

FIG. 17

Global Anti-Bacterial Drugs Market Tygacil (tigecyline) Revenues 2013 2019 (US$
Millions)

31

Global Anti-Bacterial Drugs Market Other Anti-Bacterial Drug Revenues 2013 2019
(US$ Millions)

32

FIG. 8

FIG. 11

FIG. 15

FIG. 18
FIG. 19

Global Anti-Bacterial Drugs Market Surotomycin Revenues 2013 2019 (US$ Millions) 33

FIG. 20

Global Anti-Bacterial Drugs Market Solitaire (solithromycin) Revenues 2013 2019


(US$ Millions)

FIG. 21

34

Global Anti-Bacterial Drugs Market Delafloxacin Revenues 2013 2019 (US$ Millions) 35

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

FIG. 22

Global Anti-Bacterial Drugs Market Plazomycin Revenues 2013 2019 (US$ Millions)

36

FIG. 23

Global Anti-Bacterial Drugs Market Taksta Revenues 2013 2019 (US$ Millions)

36

FIG. 24

Global Anti-Bacterial Drugs Market Cadazolid Revenues 2013 2019 (US$ Millions)

37

FIG. 25

Global Anti-Bacterial Drugs Market Carbavance Revenues 2013 2019 (US$ Millions) 38

FIG. 26

Global Anti-Bacterial Drugs Market Eravacycline Revenues 2013 2019 (US$ Millions) 39

FIG. 27

North America Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

43

FIG. 28

Europe Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

44

FIG. 29

Asia-Pacific Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

46

FIG. 30

Latin-America Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

47

FIG. 31

Middle-East Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

48

FIG. 32

Africa Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)

49

FIG. 33

Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)

50

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

List of Tables
TABLE 1

List of companies covered in this report

13

TABLE 2

Global Anti-Bacterial Drugs Market, by Geography, 2013 - 2019 (US$ Mn) (CAGR: 2015 2019)
42

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

Chapter 1
1.1

Preface

Research Scope

Chapter Number

Segment

Description
The preface provides a brief overview of the flow of the
research report. The overview is further supplemented by a
graphical representation of the segments analyzed in the

Research Scope

report. This is followed by the postulations or assumptions

Chapter 1:

considered for analysis of different segments.

Preface

Provides

Research Methodology

Chapter 2:
Prcis

Opportunities

Anti-Bacterial Drugs

Inhibitors

&

Market Size &


Forecast Anti-

SA-BRC

while

Explains the foremost factors that are affecting the growth


(positively and negatively) of the Anti-Bacterial Drugs
Market.
Drugs

Market

Estimations

Current

Marketed

for
Anti-

Bacterial Drugs

analyzed

Teflaro/Zinforo,
Zerbaxa,

in

this

Dificid,

Avycaz,

segment

Dalvance,
Zyvox,

include

Orbactiv,

Avelox,

Cubicin,
Sivextro,

Augmentin,

Zosyn/Tazocin, Invanz and Tygacil. Estimates market value


with 2013 & 2014 as historical years and forecast of 20152019.

Chapter 5:
Pipeline Drugs

by

study.

Market Dynamics

Size & Forecast

adopted

highlights and takeaways of the market as reported in the

Inferences & Summary

Drivers,

Current Drugs Market

methodology

The chapter lists down key (quantitative and qualitative)

Chapter 3:

Chapter 4:

the

estimating the current and future market in terms of value.

Drugs analyzed in this segment include Surotomycin,


Market Estimations for AntiBacterial Drugs in Pipeline

Solithromycin, Delafloxacin, Plazomycin, Taksta, Cadazolid,


Carbavance, Eravacycline and Others. Estimates market
value with forecast between 2015 and 2019 based on

Bacterial Drugs

estimated approval dates.

Chapter 6:

Provides estimates by value for 6 geographies of North

Geography Market
Size & Forecast

America, Europe, Asia-Pacific, Latin America, Middle-East

Demographical Analysis

and Africa. Estimates with 2013 & 2014 as historical years


and forecast of 2015-2019.

Anti-Bacterial Drugs

Elaborates the market share of key players (2014), recent

Chapter 7:

Recent

Key Player Analysis

Competitive Strategies

Developments

&

developments for the years 2013, 2014 & 2015 and major
competitive strategies adopted by companies in this area
based on events for past 2 years.

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

Chapter 8:

Postscript

Epilogue

Overview

qualitative

Provides postscript content to the report and includes an


informal perspective on the market with the best possible
outcome by the end of forecast period.
Merck & Co, Cubist Pharmaceuticals, Astrazeneca, Forest
Laboratories, Johnson & Johnson (Janssen Pharma), Mpex

Companies Covered:

Qualitative and Quantitative


Analysis

Pharmaceuticals,
Therapeutics,

Targanta

Paratek

Pharmaceuticals,

Therapeutics,

Pharmaceuticals,

Actavis

Nektar

Pfizer,

Pharmaceuticals,

Cempra
Optimer

Pharmaceuticals, GlaxoSmithKline (GSK), Takeda , Durata


Therapeutics, Melinta, The Medicines Company, etc.

1.1.1 Market Segmentation


FIG. 1

Market Segmentation: Anti-Bacterial Drugs Market Assessment & Forecast (2015-2019)

Antibacterial Drugs Market

Current Drugs

Pipeline Drugs

Geography

Cubicin

Surotomycin

North
America

Teflaro/Zinforo

Solithromycin

Europe

Dificid

Delafoxacin

Dalvance

Plazomycin

Orbactiv

Asia-Pacific

Latin America

Taksta
Middle-East

Sivextro
Cadazolid

Africa

Zerbaxa

Carbavance
Avycaz
Eravacycline

Zyvox
Avelox

Augmentin
Zocyn/Tazocin
Tygacil
Invanz

Source: SA-BRC Analysis

10

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

1.2

Methodology of Research

FIG. 2

Research Methodology: Global Anti-Bacterial Drugs Market Assessment

Primary Research

Quantitative

Research

Online-web (CATI/CAWI/CAPI)
Telephonic and video conference
Interviewee Location: Multiple
respondents from each of 6 geographies
Interviewee Field Exp.: All Interviewees
were c-level, d-level, VP level and senior
management
Target Information: validation of
secondary findings; cross-verification of
other primary interviews,
Organization Research Institutes,
Manufacturers, Distributors, Resellers

Secondary/Desk Research

Primary Research

Qualitative
Research

Scientist blogs
Online communities/Scientist Forums
Online chat with KOLs/experts
Focused Group Discussions
Target Information: Insights on market
trends, market impact factors, marketing
and awareness programs etc.

Proprietary third party databases


In-house data repository
Company websites
Annual Reports/ SEC Filings
Investor presentations
Equity & Stock
(Seeking Alpha, Zacks, Medical Buyer,
Fierce Pharma, Market Watch, Wall
Street Journal, etc.)

Secondary/Desk Research

Unicef.org, CDC, WHO, NHS, NIH


Nature.com, ipwatchdog.com,
Accessdata, U.S. FDA, Bloomberg
USPTO.gov, espacenet.com
IMS Health
Bloomberg
Cegedim
Company websites and investor
presentations.

Spearhead-Acuity Team

Key Findings
Market Forecast
Insight Generation

Data triangulation was done for the information (quantitative/qualitative) collected through
primary and secondary sources. Analysis also included evaluation of all major macro and
microeconomic factors.
Post data triangulation process, the summary of our study was shared with KOLs and industry
experts to suggest further insights to our analysis as well as validate the overall Anti-Bacterial
Drugs Market.

Source: SA-BRC Analysis. **Websites mentioned in the above representation are few examples from our exhaustive list of references that
cannot be compiled in entirety

12

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

1.2.1 Companies cover ed in this r eport


TABLE 1

List of companies covered in this report

S.No

Company Name

S.No

Company Name

Merck & Co

Pfizer

Cubist Pharmaceuticals

Cempra Pharmaceuticals

Astrazeneca

Actavis Pharmaceuticals

Forest Laboratories

Optimer Pharmaceuticals

Johnson & Johnson (Janssen Pharma)

10

GlaxoSmithKline (GSK)

11

Mpex Pharmaceuticals

12

Takeda

13

Targanta Therapeutics

14

Durata Therapeutics

15

Nektar Therapeutics

16

Melinta

17

Paratek Pharmaceuticals

18

The Medicines Company

Source: Proprietary data sources, KOL opinions, Primary Interviews, SA-BRC Analysis

13

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

Disclaimer:

SA-BRC Market Research is an informative Market Research Company with the sole intention of
sharing market related insights. The information provided in our research reports or on sa-brc.com
though collected through authentic sources, analyzed and cross validated through Key Opinion
Leaders (KOLs) in the industry; neither the company nor authors provide any kind of warranty about
the content both qualitative and quantitative.

Contact
John Whitmore
10685-B Hazelhurst Dr. #17411
Houston, TX 77043
United States
Contac Number: +1(832)-426-3701
Email: john@sa-brc.com, sales@sa-brc.com
Website: www.sa-brc.com

56

You might also like